What is Fresh Frozen Plasma?
Fresh Frozen Plasma (FFP) is a blood product prepared by separating plasma from whole blood and freezing it within 8 hours of collection at -18°C or colder. It contains all the coagulation factors, fibrinogen, albumin, protein C, protein S, and antithrombin in physiological concentrations. Each unit of FFP is typically 200-250 mL in volume and is derived from a single donor.
FFP is one of the most commonly transfused blood products worldwide, second only to red blood cells. It is used primarily to correct coagulation factor deficiencies when specific factor concentrates are unavailable or when multiple factors need to be replaced simultaneously. The product maintains approximately 80% of its original coagulation factor activity when properly stored and thawed.
Related products include Plasma Frozen within 24 Hours (PF24), which is frozen between 8 and 24 hours after collection and has slightly lower levels of labile coagulation factors (V and VIII), and Thawed Plasma, which is FFP that has been thawed and stored at 1-6°C for up to 5 days. Thawed Plasma retains adequate levels of most coagulation factors except Factor V and Factor VIII, which decline during refrigerated storage.
Indications for FFP Transfusion
FFP transfusion is appropriate in specific clinical scenarios where coagulation factor replacement is needed. Major indications include:
- Active bleeding with coagulopathy: When the INR is greater than 1.5-2.0 and the patient is actively bleeding or requires urgent surgery. FFP replaces the deficient coagulation factors contributing to impaired hemostasis.
- Disseminated Intravascular Coagulation (DIC): DIC involves widespread activation of the coagulation cascade, leading to consumption of clotting factors and platelets. FFP replenishes consumed factors, particularly when bleeding is the dominant clinical problem.
- Massive transfusion protocol: When a patient receives more than 10 units of red blood cells within 24 hours, dilutional coagulopathy develops. Current massive transfusion protocols recommend FFP in a 1:1 or 1:2 ratio with red blood cells to prevent and treat this coagulopathy.
- Warfarin reversal (urgent): When patients on warfarin need urgent surgery or are experiencing life-threatening bleeding, FFP can provide rapid, though partial, reversal of the anticoagulant effect. However, prothrombin complex concentrate (PCC) is now preferred for this indication as it is more effective, faster acting, and requires less volume.
- Thrombotic Thrombocytopenic Purpura (TTP): FFP is used as replacement fluid during therapeutic plasma exchange (plasmapheresis) in TTP. It provides the deficient ADAMTS13 enzyme that the patient's body either cannot produce or has developed antibodies against.
- Liver disease with bleeding: Severe liver disease impairs production of coagulation factors. FFP may be used when bleeding occurs or before invasive procedures, though its effectiveness in this setting is debated.
- Specific factor deficiency: When specific coagulation factor concentrates are not available (such as Factor V deficiency), FFP serves as the replacement source.
FFP should NOT be used for volume expansion (crystalloids or albumin are preferred), as a nutritional supplement, or prophylactically in non-bleeding patients with mildly elevated INR.
Dosing Guidelines
The standard dose of FFP is 10-20 mL/kg body weight. The typical starting dose is 10-15 mL/kg for most indications, with higher doses (15-20 mL/kg) used for severe coagulopathy or massive hemorrhage.
Units needed = Volume ÷ 250 mL per unit (rounded up)
| Patient Weight | At 10 mL/kg | At 15 mL/kg | At 20 mL/kg |
|---|---|---|---|
| 50 kg | 500 mL (2 units) | 750 mL (3 units) | 1000 mL (4 units) |
| 70 kg | 700 mL (3 units) | 1050 mL (5 units) | 1400 mL (6 units) |
| 90 kg | 900 mL (4 units) | 1350 mL (6 units) | 1800 mL (8 units) |
| 110 kg | 1100 mL (5 units) | 1650 mL (7 units) | 2200 mL (9 units) |
A dose of 10-15 mL/kg typically raises coagulation factor levels by approximately 15-25%, which is sufficient to achieve hemostasis in most situations. Post-transfusion coagulation studies (PT/INR, aPTT, fibrinogen) should be checked to assess the adequacy of replacement and guide further dosing.
In neonates and infants, the dose is the same (10-20 mL/kg), but volumes should be carefully calculated to avoid fluid overload. Irradiated and CMV-negative FFP may be required for immunocompromised pediatric patients.
Administration Procedure
Proper administration of FFP requires adherence to established transfusion protocols to ensure patient safety and product efficacy:
- Thawing: FFP must be thawed at 30-37°C using an approved water bath or microwave thawing device. Thawing typically takes 20-30 minutes for a single unit. Higher temperatures can denature coagulation factors and proteins.
- Pre-transfusion check: Two qualified personnel must verify the patient's identity, blood type, and product compatibility at the bedside before administration. ABO-compatible FFP must be used.
- Administration set: FFP is infused through a standard blood administration set with a 170-260 micron filter. No medications should be added to the FFP bag or infused through the same line simultaneously.
- Infusion rate: The initial rate should be slow (approximately 1-2 mL/minute for the first 15 minutes) to monitor for adverse reactions. If no reaction occurs, the rate can be increased. Each unit should ideally be infused within 30-60 minutes, and the entire dose should be completed within 4 hours of thawing.
- Monitoring: Vital signs should be recorded before, during (at 15 minutes), and after transfusion. Any signs of transfusion reaction (fever, chills, urticaria, dyspnea, hypotension) should prompt immediate cessation of the infusion and appropriate management.
Risks and Adverse Reactions
Like all blood products, FFP carries inherent risks that must be weighed against the clinical benefit:
- Transfusion-related acute lung injury (TRALI): The most serious non-infectious complication of FFP transfusion. TRALI presents with acute respiratory distress, bilateral pulmonary infiltrates, and hypoxemia within 6 hours of transfusion. It is caused by donor antibodies against recipient leukocyte antigens. The incidence has decreased significantly with the adoption of male-only or never-pregnant female donors for plasma products.
- Transfusion-associated circulatory overload (TACO): Particularly concerning in elderly patients, patients with heart failure, or those receiving large volumes. Symptoms include dyspnea, hypertension, and pulmonary edema. TACO is managed with diuretics and slowing or stopping the infusion.
- Allergic reactions: Range from mild urticaria (1-3% of transfusions) to anaphylaxis (rare). Mild reactions are treated with antihistamines; severe reactions require epinephrine and resuscitation.
- Febrile non-hemolytic reactions: Temperature elevation of 1°C or more during or shortly after transfusion. Usually self-limiting and managed with acetaminophen.
- Infectious transmission: Although extremely rare with modern screening, there remains a residual risk of transmitting viruses (HIV, HCV, HBV) and emerging pathogens. Pathogen reduction technologies are increasingly being applied to plasma products.
- Citrate toxicity: The citrate anticoagulant in FFP can chelate calcium, leading to hypocalcemia. This is primarily a concern during rapid, large-volume transfusion. Symptoms include perioral tingling, muscle cramps, and in severe cases, cardiac arrhythmias.
ABO Compatibility
Unlike red blood cell transfusion (where the recipient's ABO type determines compatibility), plasma transfusion follows the opposite principle because plasma contains anti-A and anti-B antibodies:
| Recipient Blood Type | Compatible FFP Types |
|---|---|
| Type A | A, AB |
| Type B | B, AB |
| Type AB | AB (only) |
| Type O | O, A, B, AB (any) |
Type AB plasma is the universal donor plasma because it contains neither anti-A nor anti-B antibodies and can be given to any recipient. This is the reverse of red blood cell compatibility, where Type O is the universal donor. In emergency situations when the recipient's blood type is unknown, AB plasma is the preferred choice.
Rh compatibility is not required for plasma transfusion because plasma does not contain red blood cells, and anti-D antibodies (when present) are in such low concentrations that they do not typically cause hemolysis.
Storage and Handling
Proper storage is critical to maintaining the coagulation factor activity of FFP:
- Frozen storage: FFP must be stored at -18°C or colder. At this temperature, it can be stored for up to 12 months from the date of collection. Some facilities store at -30°C or colder for extended shelf life.
- After thawing: Once thawed, FFP should be transfused as soon as possible. If not used immediately, it can be stored at 1-6°C for up to 24 hours and relabeled as "Thawed Plasma." Thawed Plasma stored at 1-6°C can be used for up to 5 days, though labile factors (V and VIII) decline during this period.
- Never refreeze: Once thawed, FFP must never be refrozen, as this causes protein denaturation and loss of coagulation factor activity.
- Visual inspection: Before transfusion, FFP should be visually inspected for clots, discoloration, or bag integrity issues. Units with visible abnormalities should not be used.
Frequently Asked Questions
How quickly does FFP correct coagulopathy?
The effect of FFP on coagulation parameters is immediate upon completion of the infusion, as the coagulation factors are directly provided in active form. However, the degree of correction depends on the dose administered, the severity of the coagulopathy, and ongoing consumption or loss of coagulation factors. Post-transfusion coagulation studies should be checked 15-30 minutes after completing the infusion to assess adequacy.
Can FFP be given without knowing the patient's blood type?
In emergencies, AB plasma can be given as universal donor plasma without knowing the recipient's blood type. Many trauma centers and emergency departments maintain a supply of thawed AB plasma for immediate use in hemorrhaging patients. If AB plasma is unavailable, Type A plasma is sometimes used as a second choice for unknown blood type recipients, as the anti-B antibody titer is typically lower than the anti-A titer in Type B plasma.
What is the difference between FFP and PCC?
Prothrombin Complex Concentrate (PCC) contains concentrated vitamin K-dependent coagulation factors (II, VII, IX, X) in a much smaller volume than FFP. For warfarin reversal, PCC is now preferred over FFP because it provides faster and more complete correction, requires less volume (reducing TACO risk), does not require thawing, and does not require ABO matching. However, PCC does not contain all coagulation factors and is not appropriate for all indications where FFP is used.
Is FFP effective for correcting mildly elevated INR before procedures?
Evidence does not support routine FFP transfusion to correct mildly elevated INR (less than 1.8-2.0) before procedures. Studies have shown that the bleeding risk associated with mild coagulopathy is low, and the volume of FFP needed to normalize the INR in these cases often fails to achieve complete correction while exposing the patient to transfusion risks. Clinical guidelines recommend procedure-specific assessment rather than automatic FFP administration for mild INR elevation.
What volume is one unit of FFP?
A single unit of FFP typically contains 200-250 mL of plasma, with 250 mL being the standard volume used for dosing calculations. The exact volume varies slightly between units depending on the donor's hematocrit and the collection method (whole blood-derived vs. apheresis-collected plasma). Apheresis plasma units may be larger (400-600 mL) and are sometimes split into two standard units.
Can FFP cause fluid overload?
Yes. Fluid overload (TACO) is one of the most common adverse effects of FFP transfusion, particularly in elderly patients, patients with heart failure, renal failure, or those receiving large doses. For a 70 kg patient receiving 15 mL/kg, the volume administered is over 1 liter. Diuretic pre-medication, slower infusion rates, and careful monitoring of fluid balance can help mitigate this risk. When volume overload is a significant concern, concentrated products like PCC should be considered as alternatives when clinically appropriate.